This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Alprostadil (intracavernosal)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Intracavernous injection therapy is the most effective form of pharmacotherapy for ED

  • does not require an intact nerve supply and can therefore be highly effective after spinal cord injuries and after major pelvic surgery such as after radical prostatectomy
  • due to the invasive nature of the procedure long-term compliance is poor

Alprostadil was the first and until recently was the only licensed drug approved for intracavernous ED treatment.

  • this treatment is effective in providing adequate erections - up to 80% of patients respond to treatment with intracavernosal alprostadil (1)
  • erection occurs typically 5-15 minutes after penile injection and frequently last 30-40 minutes, although the duration can be dose dependent.
  • contraindications include
    • history of hypersensitivity to alprostadil
    • a risk of priapism
    • bleeding disorders
  • requires training, reasonable manual dexterity and eyesight. Partner participation in the consultation and training programme can be valuable and improve long-term compliance.
  • a common side effect include
    • penile pain on injection (usually mild)
    • priapism may occur
    • penile fibrosis may occur - reported incidence varies from <1% to >20%. (1)

Papaverine has also been given by intracavernosal injection for impotence and is still used ‘off-license’ in some patients as monotherapy but it has more complications than alprostadil

  • a combination prepaeration of papaverine and alprostadil may be useful due to reduce side effects by using a lower dose of each drug

Recently a combination of aviptadil (formerly known as vaso-intestinal polypeptide), and phentolamine (a short-acting alpha-adrenoreceptor antagonist that also has a direct effect on smooth muscle, causing relaxation) was approved and licensed in several European countries for ED.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.